Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Nov 14

PMID 24223764

Citations 32

Authors

Iwona Hus

Agnieszka Bojarska-Junak

Sylwia Chocholska

Waldemar Tomczak

Justyna Wos

Anna Dmoszynska

Jacek Rolinski

Affiliations

Soon will be listed here.

Abstract

Th17 cells, a recently discovered subset of T helper cells that secrete IL-17A, can affect the inflammation process autoimmune and cancer diseases development. The purpose of this study was to evaluate the role of Th17 cells and IL17A in biology of CLL. The study group included 294 untreated CLL patients in different clinical stages. Here, we show that higher Th17 and IL-17A values were associated with less advanced clinical stage of CLL. Th17 cells' percentages in PB were lower in patients who died due to CLL during follow-up due to CLL (as compared to surviving patients) and in patients responding to first-line therapy with fludarabine-based regimens (as compared to non-responders). IL-17A inversely correlated with the time from CLL diagnosis to the start of therapy and was lower in patients who required treatment during follow-up. Th-17 and IL-17A values were lower in patients with adverse prognostic factors (17p and 11q deletion, CD38 and ZAP-70 expression). CLL patients with detectable IL-17A mRNA in T cells were in Rai Stage 0 and negative for both ZAP-70 and CD38 expression. Th17 percentages positively correlated with iNKT and adversely with Treg cells. The results of this study suggest that Th17 may play a beneficial role in CLL immunity.

Citing Articles

Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.

Miklos D, Riedell P, Bokun A, Chavez J, Schuster S Target Oncol. 2025; .

PMID: 40035913 DOI: 10.1007/s11523-025-01133-9.

Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia.

Gamal W, Mediavilla-Varela M, Uriepero-Palma A, Pinilla-Ibarz J, Sahakian E Int J Mol Sci. 2024; 25(12).

PMID: 38928031 PMC: 11203624. DOI: 10.3390/ijms25126324.

Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives.

Seif F, Torki Z, Zalpoor H, Habibi M, Pornour M Mol Ther Oncolytics. 2023; 28:132-157.

PMID: 36816749 PMC: 9922830. DOI: 10.1016/j.omto.2023.01.001.

The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?.

Gamal W, Sahakian E, Pinilla-Ibarz J Blood Adv. 2022; 7(11):2401-2417.

PMID: 36574293 PMC: 10238851. DOI: 10.1182/bloodadvances.2022008985.

Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia.

Liu Y, Song Y, Yin Q Front Immunol. 2022; 13:962552.

PMID: 36059445 PMC: 9437578. DOI: 10.3389/fimmu.2022.962552.

References

Lech-Maranda E, Grzybowska-Izydorczyk O, Wyka K, Mlynarski W, Borowiec M, Antosik K . Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status. Arch Immunol Ther Exp (Warsz). 2012; 60(6):477-86. DOI: 10.1007/s00005-012-0197-7. View

Ye Z, Zhou Q, Zhang J, Li X, Wu C, Qin S . CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir Res. 2011; 12:77. PMC: 3120670. DOI: 10.1186/1465-9921-12-77. View

Podhorecka M . [Apoptosis in pathogenesis of B-cell chronic lymphocytic leukemia]. Postepy Hig Med Dosw (Online). 2004; 58:236-42. View

Scrivener S, Goddard R, Kaminski E, Prentice A . Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2003; 44(3):383-9. DOI: 10.1080/1042819021000029993. View

de Jong E, Suddason T, Lord G . Translational mini-review series on Th17 cells: development of mouse and human T helper 17 cells. Clin Exp Immunol. 2009; 159(2):148-58. PMC: 2810383. DOI: 10.1111/j.1365-2249.2009.04041.x. View

Wilke C, Kryczek I, Wei S, Zhao E, Wu K, Wang G . Th17 cells in cancer: help or hindrance?. Carcinogenesis. 2011; 32(5):643-9. PMC: 3086699. DOI: 10.1093/carcin/bgr019. View

Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H . IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun. 2011; 407(2):348-54. DOI: 10.1016/j.bbrc.2011.03.021. View

Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S . Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009; 114(6):1141-9. PMC: 2723011. DOI: 10.1182/blood-2009-03-208249. View

Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A . CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer. 2003; 98(5):1089-99. DOI: 10.1002/cncr.11618. View

10.

Gaffen S . An overview of IL-17 function and signaling. Cytokine. 2008; 43(3):402-7. PMC: 2582446. DOI: 10.1016/j.cyto.2008.07.017. View

11.

Zhou P, Sha H, Zhu J . The role of T-helper 17 (Th17) cells in patients with medulloblastoma. J Int Med Res. 2010; 38(2):611-9. DOI: 10.1177/147323001003800223. View

12.

Seino K, Motohashi S, Fujisawa T, Nakayama T, Taniguchi M . Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci. 2006; 97(9):807-12. PMC: 11158813. DOI: 10.1111/j.1349-7006.2006.00257.x. View

13.

Fayad L, Keating M, Reuben J, OBrien S, Lee B, Lerner S . Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001; 97(1):256-63. DOI: 10.1182/blood.v97.1.256. View

14.

Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E . Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005; 106(6):2018-25. DOI: 10.1182/blood-2005-02-0642. View

15.

Tinhofer I, Rubenzer G, Holler C, Hofstaetter E, Stoecher M, Egle A . Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood. 2006; 108(9):2950-6. DOI: 10.1182/blood-2006-03-010553. View

16.

Bojarska-Junak A, Hus I, Szczepanek E, Dmoszynska A, Rolinski J . Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. Leuk Res. 2007; 32(2):225-33. DOI: 10.1016/j.leukres.2007.06.007. View

17.

Hus I, Podhorecka M, Bojarska-Junak A, Rolinski J, Schmitt M, Sieklucka M . The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol. 2006; 17(4):683-90. DOI: 10.1093/annonc/mdj120. View

18.

Gaffen S . The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep. 2009; 11(5):365-70. PMC: 2811488. DOI: 10.1007/s11926-009-0052-y. View

19.

Zhang J, Yan J, Xu J, Pang X, Chen M, Li L . Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009; 50(5):980-9. DOI: 10.1016/j.jhep.2008.12.033. View

20.

Palmer S, Hanson C, Zent C, Porrata L, Laplant B, Geyer S . Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol. 2008; 141(5):607-14. PMC: 3840945. DOI: 10.1111/j.1365-2141.2008.07070.x. View